Eledon pharmaceuticals announces first participant dosed in phase 2 bestow trial evaluating tegoprubart for the prevention of rejection in kidney transplantation

Trial to assess potential of tegoprubart-based immunosuppression to improve graft function compared to tacrolimus-based immunosuppression trial to assess potential of tegoprubart-based immunosuppression to improve graft function compared to tacrolimus-based immunosuppression
ELDN Ratings Summary
ELDN Quant Ranking